Articles

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during the pandemic in New York City. The pandemic dir...

Authors: Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine, Diane Marie Del Valle, Joshua Richter, Hearn Jay Cho, Shambavi Richard, Ajai Chari, Sacha Gnjatic, Miriam Merad, Sundar Jagannath, Samir Parekh and Deepu Madduri

Beyond thrombosis: the impact of tissue factor signaling in cancer

Tissue factor (TF) is the primary initiator of the coagulation cascade, though its effects extend well beyond hemostasis. When TF binds to Factor VII, the resulting TF:FVIIa complex can proteolytically cleave ...

Authors: Dusten Unruh and Craig Horbinski

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-la...

Authors: Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan and Michael Heuser

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies

High mobility group box 1 (HMGB1) is a nonhistone chromatin-associated protein that has been widely reported to play a pivotal role in the pathogenesis of hematopoietic malignancies. As a representative damage...

Authors: Shunling Yuan, Zhaoping Liu, Zhenru Xu, Jing Liu and Ji Zhang

RNA-binding proteins in tumor progression

RNA-binding protein (RBP) has a highly dynamic spatiotemporal regulation process and important biological functions. They are critical to maintain the transcriptome through post-transcriptionally controlling t...

Authors: Hai Qin, Haiwei Ni, Yichen Liu, Yaqin Yuan, Tao Xi, Xiaoman Li and Lufeng Zheng

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

The oncolytic viruses have shown promising results for the treatment of multiple myeloma. However, the use of human viruses is limited by the patients’ antiviral immune response. In this study, we investigated...

Authors: Valentina Marchica, Valentina Franceschi, Rosanna Vescovini, Paola Storti, Emanuela Vicario, Denise Toscani, Alessia Zorzoli, Irma Airoldi, Benedetta Dalla Palma, Nicoletta Campanini, Eugenia Martella, Cristina Mancini, Federica Costa, Gaetano Donofrio and Nicola Giuliani

Constructing an automatic diagnosis and severity-classification model for acromegaly using facial photographs by deep learning

Due to acromegaly’s insidious onset and slow progression, its diagnosis is usually delayed, thus causing severe complications and treatment difficulty. A convenient screening method is imperative. Based on our...

Authors: Yanguo Kong, Xiangyi Kong, Cheng He, Changsong Liu, Liting Wang, Lijuan Su, Jun Gao, Qi Guo and Ran Cheng

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Graft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte glo...

Authors: Eolia Brissot, Myriam Labopin, Ian Moiseev, J. J. Cornelissen, Ellen Meijer, Gwendolyn Van Gorkom, Montserrat Rovira, Fabio Ciceri, Laimonas Griskevicius, Didier Blaise, Edouard Forcade, Martin Mistrik, Stephan Mielke, Claude Eric Bulabois, Riitta Niittyvuopio, Eric Deconinck…

Recent advances in CAR-T cell engineering

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 C...

Authors: Ruihao Huang, Xiaoping Li, Yundi He, Wen Zhu, Lei Gao, Yao Liu, Li Gao, Qin Wen, Jiang F. Zhong, Cheng Zhang and Xi Zhang

Autoantibody signature in hepatocellular carcinoma using seromics

Alpha-fetoprotein (AFP) is a widely used biomarker for hepatocellular carcinoma (HCC) early detection. However, low sensitivity and false negativity of AFP raise the requirement of more effective early diagnos...

Authors: Shu Zhang, Yuming Liu, Jing Chen, Hong Shu, Siyun Shen, Yin Li, Xinyuan Lu, Xinyi Cao, Liangqing Dong, Jieyi Shi, Ya Cao, Xiaoying Wang, Jian Zhou, Yinkun Liu, Lei Chen, Jia Fan…

Oncolytic viruses for cancer immunotherapy

In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, an...

Authors: Otto Hemminki, João Manuel dos Santos and Akseli Hemminki

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer i...

Authors: Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai and Tingbo Liang

Measurable residual disease in multiple myeloma: ready for clinical practice?

The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable re...

Authors: Leire Burgos, Noemi Puig, Maria-Teresa Cedena, María-Victoria Mateos, Juan José Lahuerta, Bruno Paiva and Jesús F. San-Miguel

cGAS-STING, an important pathway in cancer immunotherapy

Cytosolic DNA sensing, the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, is an important novel role in the immune system. Multiple STING agonists were developed for cancer therap...

Authors: Minlin Jiang, Peixin Chen, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Lingyun Ye, Yayi He and Caicun Zhou

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pe...

Authors: Xinhua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, Lujian Liao, Bo Jiao and Ruibao Ren

Emerging therapies in mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous s...

Authors: Walter Hanel and Narendranath Epperla

The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia

Mixed-lineage leukemia (MLL) gene rearrangements trigger aberrant epigenetic modification and gene expression in hematopoietic stem and progenitor cells, which generates one of the most aggressive subtypes of leu...

Authors: Wen-Tao Wang, Tian-Qi Chen, Zhan-Cheng Zeng, Qi Pan, Wei Huang, Cai Han, Ke Fang, Lin-Yu Sun, Qian-Qian Yang, Dan Wang, Xue-Qun Luo, Yu-Meng Sun and Yue-Qin Chen

Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma

Hippo-Yes-associated protein (YAP) signaling is a key regulator of organ size and tumorigenesis, yet the underlying molecular mechanism is still poorly understood. At present, the significance of the Hippo-YAP...

Authors: Xiangxiang Zhou, Na Chen, Hongzhi Xu, Xiaoming Zhou, Jianhong Wang, Xiaosheng Fang, Ya Zhang, Ying Li, Juan Yang and Xin Wang

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Natural killer (NK) cells are powerful immune effectors, modulating their anti-tumor function through a balance activating and inhibitor ligands on their cell surface. Though still emerging, cancer immunothera...

Authors: Kyle B. Lupo and Sandro Matosevic

Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

Although research on the effects of comorbidities on coronavirus disease 2019 (COVID-19) patients is increasing, the risk of cancer history has not been evaluated for the mortality of patients with COVID-19.

Authors: Yifan Meng, Wanrong Lu, Ensong Guo, Jia Liu, Bin Yang, Ping Wu, Shitong Lin, Ting Peng, Yu Fu, Fuxia Li, Zizhuo Wang, Yuan Li, Rourou Xiao, Chen Liu, Yuhan Huang, Funian Lu…

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Melanoma patients who have detectable serum soluble NKG2D ligands either at the baseline or post-treatment of PD1/PDL1 blockade exhibit poor overall survival. Among families of soluble human NKG2D ligands, the...

Authors: Fahmin Basher, Payal Dhar, Xin Wang, Derek A. Wainwright, Bin Zhang, Jeffrey Sosman, Zhe Ji and Jennifer D. Wu

PTENP1 is a ceRNA for PTEN: it’s CRISPR clear

Here we apply state-of-the-art CRISPR technologies to study the impact that PTENP1 pseudogene transcript has on the expression levels of its parental gene PTEN, and hence on the output of AKT signaling in cancer....

Authors: Marianna Vitiello, Monica Evangelista, Yang Zhang, Leonardo Salmena, Pier Paolo Pandolfi and Laura Poliseno

The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017

Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiologic...

Authors: Ming Yi, Anping Li, Linghui Zhou, Qian Chu, Yongping Song and Kongming Wu

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti...

Authors: Laurie H. Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R. Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam and Umberto Vitolo

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognosti...

Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian and Nicholas J. Short

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programme...

Authors: Chengliang Huang, Gregory N. Gan and Jun Zhang

Th17 cells inhibit CD8⁺ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients

CD8⁺ T cell trafficking to the tumor site is essential for effective colorectal cancer (CRC) immunotherapy. However, the mechanism underlying CD8⁺ T cell infiltration in colorectal tumor tissues is not fully unde...

Authors: Dan Wang, Weina Yu, Jingyao Lian, Qian Wu, Shasha Liu, Li Yang, Feng Li, Lan Huang, Xinfeng Chen, Zhen Zhang, Aitian Li, Jinbo Liu, Zhenqiang Sun, Junxia Wang, Weitang Yuan and Yi Zhang

Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment

Exosomes are small extracellular vesicles secreted by almost all the cells. Molecular cargos of exosomes can partially reflect the characteristics of originating cells. Exosome-mediated cell-to-cell interactio...

Authors: Wenyu Wang, Youngjin Han, Hyun A Jo, Juwon Lee and Yong Sang Song

Ibrutinib dose modifications in the management of CLL

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally ...

Authors: Camille Hardy-Abeloos, Rachel Pinotti and Janice Gabrilove

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Bo Yu and Delong Liu

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang

Discovery of proangiogenic CD44+mesenchymal cancer stem cells in an acute myeloid leukemia patient’s bone marrow

Here, we report a unique acute myeloid leukemia (AML) bone marrow-derived mesenchymal stem cell (MSC) with both mesenchymal and endothelial potential, which we have named Mesenchymal Cancer Stem Cells (MCSCs)....

Authors: Huynh Cao, Jeffrey Xiao, Mark E. Reeves, Kimberly Payne, Chien Shing Chen, David J. Baylink, Guido Marcucci and Yi Xu

Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer

Expression of Oct4 maintains cancer stem cell (CSC)-like properties in lung cancer cells and is correlated with poor prognosis of lung adenocarcinoma. M2-type tumor-associated macrophages (TAMs) promote cancer...

Authors: Chia-Sing Lu, Ai-Li Shiau, Bing-Hua Su, Tsui-Shan Hsu, Chung-Teng Wang, Yu-Chu Su, Ming-Shian Tsai, Yin-Hsun Feng, Yau-Lin Tseng, Yi-Ting Yen, Chao-Liang Wu and Gia-Shing Shieh

XPO1-dependent nuclear export as a target for cancer therapy

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

Authors: Nancy G. Azizian and Yulin Li

Emerging agents that target signaling pathways in cancer stem cells

Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng

Biomarker-driven management strategies for peripheral T cell lymphoma

Peripheral T cell lymphomas are heterogeneous diseases which remain treatment challenges. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven...

Authors: Erin Mulvey and Jia Ruan

Emerging therapeutic agents for advanced non-small cell lung cancer

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances i...

Authors: Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou and Yanyan Lou

Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer

Gastrointestinal cancer, the most common solid tumor, has a poor prognosis. With the development of high-throughput sequencing and detection technology, recent studies have suggested that many chemical modific...

Authors: Qiang Wang, Wei Geng, Huimin Guo, Zhangding Wang, Kaiyue Xu, Chen Chen and Shouyu Wang

Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Peripheral T cell lymphomas form a heterogeneous group with a usually dismal prognostic. The place of allogeneic stem cell transplantation to treat PTCL is debated.

Authors: Anne-Claire Mamez, Axelle Dupont, Didier Blaise, Patrice Chevallier, Edouard Forcade, Patrice Ceballos, Mohamad Mohty, Felipe Suarez, Yves Beguin, Regis Peffault De Latour, Marie-Thérèse Rubio, Olivier Tournilhac and Stéphanie Nguyen

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data relat...

Authors: Antoine Italiano, Carine Bellera and Sandra D’Angelo

Gene modification strategies for next-generation CAR T cells against solid cancers

Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies. However, CAR T ...

Authors: Yonggui Tian, Yilu Li, Yupei Shao and Yi Zhang

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

An amendment to this paper has been published and can be accessed via the original article.

Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1

Human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) as a postremission treatment for standard risk Philadelphia chromosome-negative acute lymphoblastic leukemia (SR Ph-ALL) in th...

Authors: Meng Lv, Qian Jiang, Dao-Bin Zhou, Yu Hu, Dai-Hong Liu, De-Pei Wu, Jing-Bo Wang, Hao Jiang, Jing Wang, Ying-jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang

Anticancer drug R&D landscape in China

Authors: Shen Zhao, Hongyun Zhao, Cheng Lv, Jifang Gong, Jian Zhang, Wenfeng Fang, Jin Li, Xichun Hu, Yi Ba, Binghe Xu, Yanqiao Zhang, Yun Fan, Kunyan Li, Xiaoyuan Chen, Zhimin Yang, Lin Shen…

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of th...

Authors: Xin Li and Yongcheng Song

Relative survival in early-stage cancers in the Netherlands: a population-based study

In this nationwide, population-based study, we assessed 10-year relative survival among 225,305 patients with ten early-stage cancers diagnosed in the Netherlands during 2004–2015. This study aimed to ascertai...

Authors: Avinash G. Dinmohamed, Valery E. P. P. Lemmens, Ignace H. J. T. de Hingh and Otto Visser

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocyt...

Authors: Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng…

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an i...

Authors: Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang…

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched ...

Authors: Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Emanuele Angelucci, Fabio Ciceri, Didier Blaise, Jan J. Cornelissen, Ellen Meijer, J. L. Diez-Martin, Yener Koc, Montserrat Rovira, Luca Castagna, Bipin Savani, Annalisa Ruggeri, Arnon Nagler…

How to select IgG subclasses in developing anti-tumor therapeutic antibodies

The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the four subclasses of human IgG...

Authors: Jifeng Yu, Yongping Song and Wenzhi Tian